For instance, BACE1 inhibitors and anti-amyloid-β biologics reduce amyloid-β deposits in the brain that are thought to be a cause of Alzheimer’s disease, the most prevalent form of dementia. This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.